Premium
Comparative evaluation study of polycomplex carriers based on Eudragit® EPO / S100 copolymers prepared in different media
Author(s) -
Bukhovets Aleksandra V.,
Sitenkov Alexander Y.,
Moustafine Rouslan I.
Publication year - 2021
Publication title -
polymers for advanced technologies
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.61
H-Index - 90
eISSN - 1099-1581
pISSN - 1042-7147
DOI - 10.1002/pat.5284
Subject(s) - swelling , copolymer , diclofenac sodium , nuclear chemistry , hydrogen bond , theophylline , ionic bonding , materials science , drug delivery , polymer chemistry , chemical engineering , chemistry , chromatography , polymer , organic chemistry , molecule , pharmacology , ion , medicine , engineering , composite material
Abstract Interpolymer complexes (IPC) Eudragit® EPO/S100 were prepared in different media (water pH of 7.0 and ethanol). According to the elemental analysis, FTIR spectroscopy, and thermal analysis data, IPC prepared in aqueous media (denoted as interpolyelectrolyte complexes—IPECs) is stabilized predominantly by ionic intermacromolecular bonds and has a composition close to equimolar. However, polycomplexes formed in nonaqueous (ethanol) media (denoted as IPC) are stabilized by both hydrogen and ionic bonds and characterized by an almost twofold excess of Eudragit® S100. All samples do not include free copolymer domains. IPECs and IPCs have different behavior in the buffer media mimicking the gastrointestinal tract. Matrices of IPECs are characterized by the surface erosion and pH‐independent swelling profiles with low values of a swelling degree. Matrices of the IPCs swell significantly in the buffer media with pH 1.2, 5.8, and 6.8 with subsequent decrease in the swelling degree due to the surface erosion. According to the assessment of release of the model active pharmaceutical ingredient (API), IPECs are prospective carriers for sustained delivery of II class Biopharmaceutical Classification System (BCS) drug (diclofenac sodium). At the same time, IPCs provide sustained release of the II class BCS and prolonged release of the I class BCS drug (theophylline).